STOCK TITAN

Scisparc Stock Price, News & Analysis

SPRC Nasdaq

Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.

SciSparc Ltd. (Nasdaq: SPRC) generates news across clinical-stage pharmaceuticals, intellectual property, medical devices, and advanced computing initiatives. Through its majority-owned subsidiary NeuroThera Labs Inc., the company reports progress on cannabinoid-based drug candidates, patent grants, and collaborations targeting central nervous system and neuropsychiatric disorders.

Investors following SPRC news can expect updates on drug development programs such as SCI-110, for Tourette syndrome and for the treatment of Alzheimer’s disease and agitation, and SCI-210, for autism spectrum disorder (ASD) and status epilepticus. Company announcements also cover patent activity, including NeuroThera’s opioid–N-acylethanolamine platform for pain management and MEAI-based combination therapies for depression and addiction-related indications.

SciSparc’s news flow extends to corporate transactions and strategic repositioning. Recent disclosures include the transfer of its advanced clinical-stage pharmaceutical portfolio and its stake in SciSparc Nutraceuticals Inc. into NeuroThera Labs Inc., the sale of oncology-focused subsidiary MitoCareX Bio Ltd. to N2OFF, Inc., and a binding term sheet followed by a definitive agreement to acquire a treasury of patents and trademarks for innovative endoscopic systems and medical cameras, including the MUSE system for GERD treatment.

Another recurring theme in SPRC news is technology-driven R&D. The company has announced a quantum computing-enabled 3D protein modeling initiative aimed at improving drug discovery, as well as a non-binding term sheet for NeuroThera to acquire a majority stake in a quantum bio data analysis company. Regulatory and capital markets items, such as Nasdaq compliance notifications, warrant inducement agreements, and SEC Form 6-K filings, also appear in its news stream. For a structured view of these developments, the SciSparc news page aggregates press releases and related coverage in one place.

News
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.78%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.11%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags

FAQ

What is the current stock price of Scisparc (SPRC)?

The current stock price of Scisparc (SPRC) is $0.564 as of February 20, 2026.

What is the market cap of Scisparc (SPRC)?

The market cap of Scisparc (SPRC) is approximately 2.9M.

SPRC Rankings

SPRC Stock Data

2.87M
3.05M
Biotechnology
Healthcare
Link
Israel
Tel Aviv

SPRC RSS Feed